Niagen Bioscience Inc (FRA:OCD1)

Q3 2025 Niagen Bioscience Inc Earnings Call Transcript

Nov 4, 2025 / 09:30 PM GMT

Release Date Price: €6 (-4.00%)

Transcript 8-K10-Q

Key Points

Positve

Niagen Bioscience Inc (NAGE) reported a record performance with $34 million in revenue, marking a 33% increase year over year.
The company achieved a net income of $4.6 million, a significant improvement from $1.9 million in the previous year.
NAGE ended the quarter with $64.3 million in cash and no debt, indicating strong financial health.
The e-commerce business showed robust growth, with net sales of $19 million, a 29% increase year over year.
A new strategic partnership was formed, providing access to a network of over 8,000 medical and healthcare practitioners, enhancing distribution and awareness of Niagen products.

Negative

The FDA's reversal on the marketing of nicotinamide mononucleotide (NMN) as a dietary supplement may face strong opposition and further challenges.
Despite the FDA's decision, companies continue to sell NMN, potentially infringing on existing patents owned by Niagen Bioscience Inc (NAGE).
The at-home injection kits are currently only available through clinics, with full telehealth integration expected to take several months.
The high pricing of NAD IVs and injections in clinics may limit consumer adoption and market growth.
The impact of the FDA's decision on NMN has not yet resulted in significant changes in consumer purchasing behavior.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NAGE.OQ - Niagen Bioscience Inc
Q3 2025 Niagen Bioscience Inc Earnings Call
Nov 04, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by and welcome to the Nigin Biosciences Inc. 3rd quarter of 2025 earnings conference call. My name is Tamika, and I will be your conference operator today. At this time, all participants are in a listen-only mode, and as a reminder, this conference call is being recorded.

This afternoon Nigent Biosciences issued a news release announcing the company's financial results for the 3rd quarter of 2025.

If you have not reviewed this information, both are available within the investor relations section of Nigent Bioscience's website at www.knowgenscience.com. I would now like to turn the conference over to Kendall Knish, senior director of publicity and public relations.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.